萘普生2-芳基吗啉乙酯的合成及其对环氧合酶-2的抑制活性

基于萘普生的构效关系对其羧基进行结构修饰, 设计合成了萘普生2-芳基吗啉乙酯类化合物. 芳基乙酮经过溴代、胺化、还原得到的2-芳基-4-羟乙基吗啉在三乙胺作缚酸剂存在下与萘普生酰氯反应得到萘普生2-芳基吗啉乙酯类化合物, 收率24.2%～76.5%. 新化合物结构经1H NMR确认. 生物活性实验结果表明: 在10 μmol/L质量浓度时, 化合物1d对COX-2的抑制率达96.32%.     

布洛芬衍生物的合成及抗炎镇痛活性

基于环氧合酶-2(COX-2)与COX-1结构上的差异, 设计了在布洛芬苯环3位引入取代苯甲酰胺基的系列化合物, 以期利用COX-2的侧面口袋, 增加对COX-2的结合作用. 以布洛芬为原料经五步反应合成12个目标化合物, 其结构经核磁共振氢谱、质谱和元素分析(或高分辨质谱)确证. 体外筛选结果表明, 化合物有一定的COX-2抑制活性; 对化合物7g和7h进行了体内实验, 结果表明抗炎活性弱, 但镇痛活性比较强.     

2,5-二取代-1,3,4-噻二唑衍生物的一锅法合成、结构表征及生物活性研究

采用超声波辐射与相转移催化联用技术, 一锅法合成出了8个新的2-(1-萘乙酰氨基)-5-芳氨甲基-1,3,4-噻二唑化合物, 这种合成方法具有反应条件温和、反应时间较短、产率较高等特点. 新化合物的结构利用IR, ¹H NMR, ¹³C NMR, 1D NOE, MS和元素分析进行了表征. 人环氧酶-2 (COX-2)活性抑制实验结果表明, 目标化合物5f对COX-2具有很强的抑制活性, 抑制率高达95.59%; 化合物5g对COX-2也具有一定的抑制活性. 目标化合物无抗惊厥活性.     

1,8-萘酰亚胺类衍生物的合成及细胞活性研究

以4-溴-1,8萘二甲酸酐作为先导化合物,通过氨解、亲核取代合成了9个1,8-萘酰亚胺类衍生物,通过质谱(MS)、核磁共振氢谱(1H-NMR)、核磁共振碳谱(13C-NMR)表征其结构,采用CCK8法检测目标化合物对乳腺癌MCF-7、肺癌H460、肝癌HepG2的细胞活性.结果表明,9个衍生物中目标化合物3b的体外抗肿...     

一种萘酰亚胺衍生物的合成及其体外抗癌活性测定

合成了萘酰亚胺衍生物2-[2-(二甲基氨基)乙基]-6-2-(2-羟乙胺基)乙胺基-1H-苯并异喹啉-1,3(2H)-二酮;利用元素分析、核磁共振谱及质谱分析了其组成和结构;利用MTT法测定了其对人肝癌细胞(HepG2)、人乳腺癌细胞(MDA-MB-231)及人结肠癌细胞(HCT-116)的体外活性.结果表明,标题化合物的体外抗肿瘤活性优于对照品氨萘非特.     

1-[5-(α-萘)-2H-四唑-2-乙酰基]-4-芳酰基胺基硫脲和3-[5-(α-萘)-2H-四唑-2-亚甲基]-4-芳酰基-1,2,4-三唑啉-5-硫酮的合成

本文通过5-(α-萘)-2H-四唑-2-乙酰肼(Ⅰ)与芳酰基异硫氰酸酯缩合制得16种新的1-[5-(α-萘)-2H-四唑-2-乙酰基]-4-芳酰基胺基硫脲(Ⅱ),(Ⅲ)在碱性催化条件下环化为3-[5-(α-萘)-2H-四唑-2-亚甲基]-4-芳酰基-1,2,4-三唑啉-5-硫酮(Ⅲ),化合物的结构经元素分析,IR、~1H NMR和MS鉴定,对化合物(Ⅲ)的质谱裂解进行分析,解释了化合物(Ⅱ)的环化方向,经初步筛选,发现个别化合物对小麦胚芽生长有促进作用。     

基于萘普生-芳基金属配合物的抗癌及抗炎性能

以萘普生(NPX)为前体, 分别与芳基钌(Ru)、 锇(Os)及铱(Ir)二聚体反应制备了3个单核配合物[Ru(η ⁶-p-cymene)(NPX-bpy)Cl]Cl(1), [Os(η ⁶-p-cymene)(NPX-bpy)Cl]Cl(2)和[Ir(η ⁵-Cp ^*)·(NPX-bpy)Cl]Cl(3). 利用元素分析、 电喷雾质谱和核磁共振波谱对3个配合物的组成和结构进行了表征, 并研究了其细胞毒性. 结果表明, 3个配合物对几种肿瘤细胞株均无毒性(IC₅₀>100 μmol/L), 仅配合物1对NB-4细胞有中等程度的毒性(IC₅₀=45.2 μmol/L), 且毒性大于配合物2和3, 这可能与配合物1在细胞核内具有更高的富集量有关. 此外, 3个配合物均可有效抑制COX-2的表达, 保留了萘普生的抗炎性质, 实现了金属配合物抗癌及抗炎的多功能化应用.     

NH4Cl催化一步合成2-萘酚类缩胺基硫脲类化合物

报道了在室温,以CHC13为溶剂,NH4Cl为催化剂,醛、2-萘酚及氨基硫脲(物质的量比为2∶1∶1)通过一步多组份偶合反应有效地合成了一系列的2-萘酚类缩胺基硫脲化合物,均得到了较好的收率.所有目标化合物均通过熔点测定,并用质谱、红外光谱、核磁共振谱、元素分析对其结构进行确证.     

铜(II)化合物作用下2-萘胺的氧化偶合反应

2 萘胺 (1)在甲醇中与铜胺络合物 [x(CuCl2 )∶x(苄胺或乙醇胺 ) =2∶1]室温下反应得到产率为 74 %的 1,1′ 联 2 萘胺 (2 ) .在醋酸铜、硝酸铜或高氯酸铜的催化下 ,1在甲醇中被氧气氧化为 2 氨基 1,4 萘醌 4 2′ 萘亚胺 (3) ,产率86 % .用X ray单晶衍射证实 3的乙酰化产物结构为 2 乙酰氨基 1,4 萘醌 E 4 2′ 萘亚胺 (4) .循环伏安研究表明 ,铜 (II)化合物的氧化反应选择性与其还原峰电位有关 .电喷雾质谱的分析表明 1,2 萘醌 2 亚胺 (6 )是生成 3的中间体     

(S)-萘普生-1,4-二氢吡啶类化合物的合成与生物活性

以(S)-萘普生为原料制得的(S)-萘普生氯甲酯与1,4-二氢吡啶-3,5-二羧酸单酯在无水K₂CO₃存在下于DMF中反应得到的粗产品经梯度结晶或柱层析纯化得标题化合物. 合成的7种目标化合物收率21%～73%, 经¹H NMR, IR, MS确证了结构. 家兔离体血管平滑肌收缩试验研究表明, 大部分目标化合物对苯肾上腺素诱导的血管收缩有松弛作用.     

Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus

There is an urgent need for specific antiviral treatments directed against SARS-CoV-2 to prevent the most severe forms of COVID-19. By drug repurposing, affordable therapeutics could be supplied worldwide in the present pandemic context. Targeting the nucleoprotein N of the SARS-CoV-2 coronavirus could be a strategy to impede viral replication and possibly other essential functions associated with viral N. The antiviral properties of naproxen, a non-steroidal anti-inflammatory drug (NSAID) that was previously demonstrated to be active against Influenza A virus, were evaluated against SARS-CoV-2. Intrinsic fluorescence spectroscopy, fluorescence anisotropy, and dynamic light scattering assays demonstrated naproxen binding to the nucleoprotein of SARS-Cov-2 as predicted by molecular modeling. Naproxen impeded recombinant N oligomerization and inhibited viral replication in infected cells. In VeroE6 cells and reconstituted human primary respiratory epithelium models of SARS-CoV-2 infection, naproxen specifically inhibited viral replication and protected the bronchial epithelia against SARS-CoV-2-induced damage. No inhibition of viral replication was observed with paracetamol or the COX-2 inhibitor celecoxib. Thus, among the NSAID tested, only naproxen combined antiviral and anti-inflammatory properties. Naproxen addition to the standard of care could be beneficial in a clinical setting, as tested in an ongoing clinical study.     

Design, synthesis and preliminary pharmacological evaluation of new non-steroidal anti-inflammatory agents having a 4-(methylsulfonyl) aniline pharmacophore

A series of 4-(methylsulfonyl)aniline derivatives were synthesized in order to obtain new compounds as a potential anti-inflammatory agents with expected selectivity against COX-2 enzyme. In vivo acute anti-inflammatory activity of the final compounds 11-14 was evaluated in rat using an egg-white induced edema model of inflammation in a dose equivalent to 3 mg/Kg of diclofenac sodium. All tested compounds produced significant reduction of paw edema with respect to the effect of propylene glycol 50% v/v (control group). Moreover, the activity of compounds 11 and 14 was significantly higher than that of diclofenac sodium (at 3 mg/Kg) in the 120-300 minute time interval, while compound 12 expressed a comparable effect to that of diclofenac sodium in the 60-240 minute time interval time, and compound 13 showed a comparable effect to that of diclofenac sodium at all experimental times. The result of this study indicates that the incorporation of the 4-(methylsulfonyl)aniline pharamacophore into naproxen, indomethacine, diclofenac and mefanamic acid maintained their anti-inflammatory activity and may increase selectivity towards the COX-2 enzyme which will be confirmed in the future by assessing COX-2: COX-1 inhibitory ratios using a whole blood assay.     

Breast Cancer Stem Cell Potency of Nickel(II)-Polypyridyl Complexes Containing Non-steroidal Anti-inflammatory Drugs

We report the breast cancer stem cell (CSC) potency of two nickel(II)-3,4,7,8-tetramethyl-1,10-phenanthroline complexes, 1 and 3 , containing the non-steroidal anti-inflammatory drugs (NSAIDs), naproxen and indomethacin, respectively. The nickel(II) complexes, 1 and 3 kill breast CSCs and bulk breast cancer cells in the micromolar range. Notably, 1 and 3 display comparable or better potency towards breast CSCs than salinomycin, an established CSC-active agent. The complexes, 1 and 3 also display significantly lower toxicity towards non-cancerous epithelial breast cells than breast CSCs or bulk breast cancer cells (up to 4.6-fold). Mechanistic studies suggest that 1 and 3 downregulate cyclooxygenase-2 (COX-2) in breast CSCs and kill breast CSCs in a COX-2 dependent manner. Furthermore, the potency of 1 and 3 towards breast CSCs decreased upon co-treatment with necroptosis inhibitors (necrostatin-1 and dabrafenib), implying that 1 and 3 induce necroptosis, an ordered form of necrosis, in breast CSCs. As apoptosis resistance is a hallmark of CSCs, compounds like 1 and 3 , which potentially provide access to alternative (non-apoptotic) cell death pathways could hold the key to overcoming hard-to-kill CSCs. To the best of our knowledge, 1 and 3 are the first compounds to be associated to COX-2 inhibition and necroptosis induction in CSCs.     

Multispecific Platinum(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX-2 and PD-L1

Breast cancer (BC) is one of the most common malignancies in women and often accompanied by inflammatory processes. Cyclooxygenase-2 (COX-2) plays a vital role in the progression of BC, correlating with the expression of programmed death-ligand 1 (PD-L1). Overexpression of PD-L1 contributes to the immune escape of cancer cells, and its blockade would stimulate anticancer immunity. Two multispecific platinum(IV) complexes DNP and NP were prepared using non-steroidal antiinflammatory drug naproxen (NPX) as axial ligand(s) to inhibit the BC cells. DNP exhibited high cytotoxicity and antiinflammatory properties superior over NP, cisplatin and NPX; moreover, it displayed potent antitumor activity and almost no general toxicity in mice bearing triple-negative breast cancer (TNBC). Mechanistic studies revealed that DNP could downregulate the expression of COX-2 and PD-L1 in vitro and vivo, inhibit the secretion of prostaglandin, reduce the expression of BC-associated protein BRD4 and phosphorylation of extracellular signal-regulated kinases 1/2 (Erk1/2), and block the oncogene c-Myc in BC cells. These findings demonstrate that DNP is capable of intervening in inflammatory, immune, and metastatic processes of BC, thus presenting a new mechanism of action for anticancer platinum(IV) complexes. The multispecificity offers a special superiority for DNP to treat TNBC by combining chemotherapy and immunotherapy in one molecule.     

青风藤有效化学成分与环氧合酶的对接研究

将青风藤中23个有效化学成分与COX-2酶对接,有四个化合物具有较低的结合自由能,其中以青藤碱为最低.进一步将这四个化合物与COX-1酶对接,发现这四个化合物与COX-1酶结合能力较弱,预示这四个化合物具有选择性抑制COX-2酶的能力.对青藤碱和COX-2以及COX-1酶的结合模式进行分析,发现青藤碱主要结合于COX-2酶的S′口袋,而COX-1酶的S′结合口袋中第523号残基由COX-2酶中的Val523变成了体积较大的Ile523,使得COX-1酶的S′结合口袋相对COX-2酶的结合口袋要小,从而导致青藤碱分子不能进入COX-1酶S′结合口袋.这成功解释了青藤碱选择性抑制COX-2酶的原因,与早期有关文献报道的实验结果相吻合,充分表明了对接模型的合理性,青藤碱等化合物可作为设计COX-2酶选择性抑制剂的先导化合物.     

Curcumin Conjugates of Non-steroidal Anti-Inflammatory Drugs: Synthesis,Structures, Anti-proliferative Assays,Computational Docking,and Inflammatory Response

In an effort to combine the anti-proliferative effect of CUR-BF₂ and CUR compounds with anti-inflammatory benefits of non-steroidal anti-inflammatory drugs (NSAIDs), a library of the bis- and mono-NSAID/CUR-BF₂ and NSAID/CUR conjugates were synthesized by coupling flufenamic acid, flurbiprofen, naproxen, indomethacin, and ibuprofen to diversely substituted hydroxy-benzaldehydes via an ester linkage, and by subsequent reaction with acetylacetone-BF₂ to form the bis- and the mono-NSAID/CUR-BF₂ adducts. Since conversion to NSAID/CUR by the previously developed decomplexation protocol showed limited success, a set of NSAID/CUR conjugates were independently prepared by directly coupling the NSAIDs with parent curcumin. The bis-NSAID/CUR-BF₂ and bis-NSAID-CUR hybrids exhibited low cytotoxicity in NCI-60 assay, and in independent cell viability assay on colorectal cancer (CRC) cells (HCT116, HT29, DLD-1, RKO, SW837, CaCo2) and in normal CR cells (CCD841CoN). By contrast, the mono-naproxin and mono-flurbiprofen CUR-BF₂ adducts exhibited remarkable anti-proliferative and apoptopic activity in NCI-60 assay most notably against HCT-116 (colon), OVCAR-3 (ovarian), and ACHN (renal) cells. Computational molecular docking calculations showed favorable binding energies to HER2, VEGFR2, BRAF, and Bcl-2 as well as to COX-1 and COX-2, which in several cases exceeded known inhibitors. The main interactions between the ligands and the proteins were hydrophobic, although several hydrogen bonds were also observed. A sub-set of six compounds that had exhibited little or no cytotoxicity were tested for their anti-inflammatory response with THP-1 human macrophages in comparison to parent NSAIDs or parent curcumin.     

Isolation and characterization of phenolic compounds from the leaves of Salix matsudana

A bioassay-guided in vitro screen has revealed that a 70% methanol extract of the leaves of Salix matsudana shows considerable inhibitory activity against cyclooxygenases (COX-1 and COX-2). A subsequent phytochemical study led to the isolation of a new flavonoid, matsudone A (1), together with five known flavonoids--luteolin (2), isoquercitrin (3), 7-methoxyflavone (4), luteolin 7-O-glucoside (5), 4',7-dihydroxyflavone (6)--and two phenolic glycosides, leonuriside A (7) and piceoside (8). Their structures were elucidated on the basis of extensive 1D- and 2D-NMR studies, high resolution ESI mass spectroscopic analyses and comparisons with literature data. The isolated compounds 1-8 were tested for their inhibitory activities against COX-1 and COX-2. Compounds 1, 5 and 6 were found to have potent inhibitory effect on COX-2 and compounds 3-5 exhibited moderate inhibition against COX-1.